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indirect mechanisms. The mechanism of transcriptional regulation of IRF4 and miR-23 155HG by EBNA2 however has not been defined. We demonstrate that EBNA2 can 24 activate IRF4 and miR-155HG expression through specific upstream enhancers that are 25 dependent on the Notch signaling transcription factor RBPJ, a known binding partner of 26 EBNA2. We demonstrate that in addition to activation of the miR-155HG promoter, IRF4 27 can also activate miR-155HG via the upstream enhancer also targeted by EBNA2. Gene 28 editing to remove the EBNA2-and IRF4-responsive miR-155HG enhancer located 60 kb 29 upstream of miR-155HG led to reduced miR155HG expression in EBV-infected cells. Our 30 data therefore demonstrate that specific RBPJ-dependent enhancers regulate the IRF4-31 miR-155 expression network and play a key role in the maintenance of miR-155 expression 32 in EBV-infected B cells. These findings provide important insights that will improve our 33 understanding of miR-155 control in B cell malignancies. 34 35 IMPORTANCE 36 is expressed at high level in many human cancers particularly 37 lymphomas. Epstein-Barr virus (EBV) infects human B cells and drives the development 38 growth and a likely driver of lymphoma development. 48 49 INTRODUCTION include transcription regulators, receptors and signaling pathway components e.g. HDAC4, 73 PIK3R1, SMAD5, SHIP1, PU.1, BCL2 and C/EBPβ (10, 11) . in their viral genomes (15) (16) (17) . 86 87 Two EBV genes essential for B cell transformation upregulate miR-155 expression; the 88 constitutively active CD40 receptor mimic, latent membrane protein 1 (LMP1) and the 89 viral transcription factor, Epstein-Barr virus nuclear antigen 2 (EBNA2) (13, 14) . 90 Expression of either LMP1 or EBNA2 independently activates transcription of miR-155HG 91 (14) . Upregulation of AP-1 and NF-B activity by LMP1 appears to play an important role 92 in activation of the miR-155 promoter in EBV-infected cells (18, 19) . The mechanism of 93 EBNA2 activation of miR-155 has not been demonstrated. EBNA2 is required for B cell 94 immortalization by EBV and activates all viral gene promoters, including LMP1, so 95 indirect activation of miR-155 via upregulation of LMP1 is a likely consequence of 96 EBNA2 expression (20, 21) . However, EBNA2 also deregulates host gene transcription by 97 binding to promoter and enhancer elements (22, 23) . activation by EBNA2 appears to be widespread in the B cell genome (23) (24) (25) . For example, 99 EBNA2 activation of the MYC proto-oncogene is directed by the targeting of upstream 100 enhancers and modulation of enhancer-promoter looping (22, 26) . EBNA2 does not bind 101 DNA directly and associates with viral and cellular gene regulatory elements through its 102 interactions with cellular transcription factors that include RBPJ, PU.1 and EBF1 (27) . 103 104 An EBNA2-bound super-enhancer postulated to control miR-155 expression was 105 identified in LCLs based on the binding of a number of EBV transcription factors (EBNA2, 106 EBNA3A, EBNA3C and EBNA-LP), binding of NF-B subunits and broad and high 107 histone H3 lysine 27 acetylation signals (25). However, the original region identified 108 actually comprises the highly expressed 20 kb miR-155HG transcription unit from which 109 miR-155 is derived. A subsequent study using RNA polymerase II (RNA pol II) chromatin 110 interaction analysis by paired-end tag sequencing (ChIA-PET) found that RNA pol II 111 associated with a number of EBNA2-bound promoter, enhancer and super-enhancer 112 regions upstream of mIR-155HG that formed links with the mIR-155HG promoter (28). 113
Whether EBNA2 can activate miR-155HG transcription via the miR-155HG promoter or 114 these putative enhancer elements however has not been investigated. 115 116 MiR-155 expression is also activated by interferon regulatory factor 4 (IRF4) through an 117 interferon-stimulated response element (ISRE) in the miR-155HG promoter (29). 118
Interestingly, IRF4 levels are highly upregulated in EBV infected cells and like miR-155, 119 IRF4 is also induced by both LMP1 and EBNA2 (30). As a result, IRF4 and miR-155 levels 120 correlate in EBV infected cells. In addition to the potential indirect effects of EBNA2 on 121 IRF4 expression via LMP1 upregulation, conditional expression of EBNA2 in the presence 122 of protein synthesis inhibitors also demonstrates that IRF4 is a direct target gene of EBNA2 123 (31). The mechanism of EBNA2 activation of IRF4 has not been demonstrated. IRF4 124 expression is essential for the growth and survival of LCLs and apoptosis induced by IRF4 125 depletion can be partially rescued by expression of miR-155 (29, 32) . This indicates that 126 the upregulation of miR-155 by IRF4 may be a key component of its essential role in 127 promoting LCL growth. 128
129
To obtain important information on how the IRF4/miR-155 expression network is 130 controlled by EBV, we investigated the role of putative upstream EBNA2-bound enhancer 131 elements in the regulation of miR-155HG and IRF4 expression. At both gene loci we 132 identified specific EBNA2-bound enhancer elements that activate transcription of their 133 respective promoters in an RBPJ-dependent manner. Deletion of the EBNA2-responsive 134 miR-155HG enhancer resulted in a decrease in mIR-155HG transcription in EBV-infected 135 cells demonstrating its importance for the maintenance of miR-155 expression. These data 136
identify key enhancer elements utilized by EBV for the control of two genes critical for B 137 cell growth that is relevant to the study of miR-155 and IRF4 deregulation in other tumor 138 contexts. 139
140

RESULTS
141
A miR-155HG upstream enhancer is activated by EBNA2 through RBPJ 142
To obtain information on regulatory elements that may control miR-155 expression, we 143 examined miR-155HG promoter interaction data obtained by the genome-wide 144 chromosome conformation technique, capture Hi-C (CHi-C) ( Figure 1) . In both the 145 GM12878 LCL and in CD34+ hematopoietic progenitor cells, the miR-155HG promoter 146 interacts with three main upstream regions marked by high levels of H3K27ac indicating 147 transcription regulatory function. These include two intergenic regions and an intragenic 148 region proximal to the promoter of the LINC00158 non-coding RNA gene ( Figure 1 ). The 149 same miR-155HG interacting regions were also detected by RNA pol II ChIA-PET (28). 150
Interestingly, CHi-C data demonstrates that the miR-155 genomic locus within exon 3 of 151 miR-155HG interacts at a much lower frequency with the two intergenic regions ( Figure  152 1). This suggests that these interactions more frequently involve the miR-155HG promoter, 153 consistent with a role in regulating transcription. The miR-155 genomic locus does 154 however interact with the LINC00158 promoter proximal region, consistent with a gene to 155 gene looping interaction between miR-155HG and LINC00158 (Figure 1 ). The miR-156 155HG-LINC00158 interaction is also the main interaction detected in this region by PET for the chromatin organizing factor CTCF, suggesting it may be involved in domain 158 organization rather than miR-155HG promoter regulation (28). Our EBNA2 chromatin 159 immunoprecipitation ChIP-sequencing data from the same LCL used for CHi-C detects the 160 highest EBNA2 binding at two sites within the most proximal intergenic region (24) 161 ( Figure 1 ). We therefore investigated the role of these two EBNA2-bound putative 162 enhancers in the regulation of miR155-HG. 163
164
We generated luciferase reporter plasmids containing the mIR-155HG promoter and one 165 or both of the enhancer elements (E1 and E2). Reporter assays carried out in the EBV 166 negative B cell line DG75 in the absence or presence of transient EBNA2 expression 167 demonstrated that EBNA2 had no effect on the miR-155HG promoter but activated 168 transcription up to 7.3-fold when a region encompassing both E1 and E2 was inserted 169 upstream of the promoter (Figure 2A ). The level of activation was similar to that observed 170 for the EBNA2 responsive EBV C promoter ( Figure 2B ). When testing each enhancer 171 separately, we found that the presence of E1 alone did not convey EBNA2 responsiveness, 172 but it increased basal transcription levels compared to the promoter alone by approximately 173 2-fold ( Figure 2A ). This indicates that E1 has EBNA2-independent enhancer function. 174 EBNA2 activated transcription via E2 alone up to 10.8-fold indicating that E2 is an 175 EBNA2-responsive enhancer (Figure 2A ). Interestingly, the presence of E2 decreased 176 basal transcription levels approximately 5-fold compared to the promoter alone ( Figure  177 2A). This is consistent with the presence of repressive elements in the enhancer that can 178 limit basal transcription activity, a feature we observed previously for the main EBNA2-179 responsive enhancer at RUNX3 (24). As a result, the overall level of transcription in the 180 presence of E2 was lower than that in the presence of E1 and E2 combined ( Figure 2A ). 181
Since EBNA2 upregulates IRF4 and IRF4 is a known activator of miR-155HG, we 182 investigated whether the effects of EBNA2 in these reporter assays may be indirect and the 183 result of increased endogenous IRF4 expression. We found that transient expression of 184 EBNA2 did not increase endogenous IRF4 expression ( Figure 2A ). We conclude that 185 EBNA2 independent and EBNA2-dependent enhancers regulate miR-155HG transcription 186 in EBV-infected cells and that EBNA2 activates transcription directly via association with 187 a specific miR-155HG enhancer. 188 189 EBNA2 binds to many target gene enhancers through the cell transcription factor RBPJ 190 (CBF1)(22). We investigated whether EBNA2 activation of miR-155HG E2 was mediated 191 via RBPJ. ChIP-QPCR analysis of RBPJ binding in the GM12878 LCL detected RBPJ 192 binding at E2 and not E1, consistent with a role for RBPJ in EBNA2 activation of E2 193 ( Figure 2C ). To confirm this, we carried out reporter assays in a DG75 RBPJ knock-out 194 cell line (33). This cell line was derived from a different parental DG75 cell line that also 195 lacks IRF4 expression, so for comparison we also carried out reporter assays in the parental 196 DG75 wild type cell line ( Figure 2D ). Our data demonstrated that EBNA2 activated 197 transcription of the miR-155HG E1 and E2 containing reporter construct in the wild type 198 DG75 cell line to the same extent as the EBV C promoter control, confirming our previous 199 results ( Figure 2D ). However in DG75 RBPJ knock-out cells, the activation of this reporter 200 construct by EBNA2 was almost completely abolished ( Figure 2D ). This mirrored the loss 201 of EBNA2 activation observed for the RBPJ-dependent viral C promoter ( Figure 2E ). 202
These data also provide further evidence that EBNA2 activation of miR-155HG E2 is not 203 an indirect effect mediated by IRF4 upregulation and we confirmed that IRF4 expression 204 is not induced by EBNA2 in this cell background ( Figure 2D ). 205 206 Interestingly, EBNA2 binding sites often coincide with binding sites for IRF4 or IRF4-207 containing transcription complexes, indicating that IRF4 may be involved in EBNA2 208 binding to DNA (25, 34). However, our results indicate that IRF4 is not required for 209 EBNA2 targeting of miR-155HG E2 enhancer element since EBNA2 activation was 210 efficient in the absence of IRF4 ( Figure 1D ). We conclude that EBNA2 can directly 211 upregulate miR-155HG transcription through a distal RBPJ-dependent enhancer (E2) 212 independently of IRF4. 213
214
IRF4 independently activates miR-155HG via promoter and enhancer elements 215
Our data demonstrate that IRF4 is not required for the effects of EBNA2 on miR-155HG 216 transcription. However, IRF4 can independently activate the miR-155HG promoter 217 through an ISRE (29). It is not known whether IRF4 can also activate miR-155HG 218 transcription through enhancer elements. We therefore tested whether exogenous 219 expression of IRF4 in DG75 cells can activate miR-155HG transcription via upstream 220 enhancers. Because IRF4 activates the control plasmid (pRL-TK), Firefly reporter activity 221 was normalized to actin expression as a previously described alternative in these assays 222 (35). Consistent with published data, we found that exogenous expression of IRF4 resulted 223 in a 4-fold increase in miR-155HG promoter activity (29). The presence of E1 did not result 224 in any further increase in miR-155HG transcription by IRF4 ( Figure 3 ). However, the 225 additional presence of E2 increased the activation of the miR-155HG reporter to 10-fold. 226
These data demonstrate that miR-155HG E2 is IRF4-responsive and contributes to IRF4 227 activation of miR-155HG transcription. 228
229
Taken together our results indicate that miR-155HG promoter activation by IRF4 and the 230 independent effects of IRF4 and EBNA2 on a specific miR-155HG enhancer contribute to 231 the high level expression of miR-155HG and miR-155 in EBV-infected B cells. 232 233
An IRF4 upstream enhancer is activated by EBNA2 through RBPJ 234
Our data support a role for IRF4 as a key regulator of miR-155HG expression in EBV 235 infected cells. IRF4 is also an EBNA2 target gene, but the mechanism of IRF4 upregulation 236 by EBNA2 has not been defined (29, 31) . RNA pol II ChiA-PET analysis recently 237 identified a number of upstream regions that interact with IRF4 in the GM12878 LCL (28). 238
These include the transcription unit of DUSP22, an intergenic region upstream from 239 DUSP22 predicted to be a super-enhancer and intergenic regions between IRF4 and 240 DUSP22. The upstream super-enhancer linked to both DUSP22 and IRF4, so likely 241 represents an important regulatory region (28). EBNA2 ChIP-sequencing data that we 242 obtained using EBV infected cells derived from a Burkitt's lymphoma cell line additionally 243 identified two large EBNA2 binding peaks within the region 35 kb directly upstream of 244 IRF4 ( Figure 4A ). We investigated the potential role of these regions in EBNA2 activation 245 of IRF4. These putative proximal and distal EBNA2-bound enhancer regions are referred 246 to as IRF4 enhancer 1 (E1) and IRF4 enhancer 2 (E2), respectively ( Figure 4A ). Luciferase 247 reporter assays carried out in the two different DG75 cell line clones in the absence or 248 presence of transient EBNA2 expression demonstrated that EBNA2 had a small activating 249 effect on the IRF4 promoter ( Figure 4B and D). The presence of IRF4 E1 reduced basal 250 transcription by 2-fold and increased EBNA2 activation to up to 6.6-fold similar to the 251 level of EBNA2 activation observed for the EBV C promoter ( Figure 4B ). The additional 252 inclusion of IRF4 E2 alongside IRF4 E1 had little further effect on EBNA2 activation 253 ( Figure 4B ). These data indicate that IRF4 E1 acts as an EBNA2-responsive enhancer. 254
Consistent with EBNA2 activation through RBPJ, ChIP-QPCR detected RBPJ binding at 255 IRF4 E1 and not E2 ( Figure 4C ). Accordingly, EBNA2 activation of the IRF4 enhancer 256 construct was decreased from 5.7-fold to 1.9 fold in RBPJ knock out cells. Our data 257 therefore demonstrate that EBNA2 can activate IRF4 transcription through an RBPJ-258 dependent enhancer (E1) located 13 kb upstream from the transcription start site (TSS). 259 260
Deletion of miR-155HG E2 from the B cell genome reduces mIR-155HG expression 261
Since EBNA2 and IRF4 can activate transcription through miR-155HG E2 in reporter 262 assays, we next tested the role of this enhancer in the regulation of mIR-155HG in EBV 263 infected B cells. To do this, we used CRISPR/Cas9 gene editing to remove the region 264 encompassing E2 ( Figure 5A ) from the genome of the EBV immortalized LCL IB4. We 265 designed two small guide RNAs (sgRNAs), one targeting a region 5' to the enhancer and 266 one targeting a region 3' to the enhancer, so that DNA repair following Cas9 cleavage 267 would generate an E2 deletion ( Figure 5A ). Both sgRNAs comprised 20 nucleotide 268 sequences that target the genomic region adjacent to a protospacer adjacent motif (PAM) 269 required for Cas9 cleavage ( Figure 5C ). sgRNAs were transfected into IB4 cells alongside 270
Cas9 protein and single cell clones were generated by limiting dilution. PCR screening was 271 used to identify cell line clones containing E2 deletions using a forward primer located 5' 272 of the E2 region and a reverse primer located 3' of E2 to amplify a 180 bp DNA product 273 across the deletion site ( Figure 5A and B ). This primer set did not amplify DNA from intact 274 templates containing E2 as the amplicon (1.75 kb) was too large for efficient amplification 275 under the conditions used. For three cell line clones tested (C4D, C2B and C5B) we 276 detected amplification of a 180 bp PCR product consistent with the presence of an E2 277 deletion ( Figure 5B ). We did not detect this PCR product in parental IB4 cells and an 278 additional clone, C4A indicating that this cell line clone did not contain a deletion (Figure 279 5B). Sequencing of the PCR products amplified across the deletion site confirmed the E2 280 deletion ( Figure 5C ). Clones C4D and C2B contained deletions consistent with cleavage 281 by Cas9 three bases upstream from the PAM sequence as expected, and the subsequent 282 ligation of the cleaved ends. Clone C5D had an additional deletion of 8 nucleotides at the 283 5' cut site indicating loss of a small amount of additional DNA during the DNA repair and 284 religation process ( Figure 5C ). 285 286 We next used real-time PCR analysis to determine whether deletion of miR-155HG E2 287 affected the levels of endogenous miR-155HG RNA in IB4 cells. We found that all three 288 deletion mutant cell line clones had reduced levels of miR-155HG transcripts compared to 289 parental IB4 cells or the non-deleted C4A cell line ( Figure 5D ). miR-155HG RNA 290 expression was reduced by 47%, 63% and 78% in cell line clones C4D, C2B and C5B, 291 respectively ( Figure 5D ). This indicates that the RBPJ-dependent EBNA2 responsive 292 enhancer (E2) located 60 kb upstream of miR-155HG plays an important role in 293 maintaining miR-155HG expression in EBV infected cells. Given that miR-155 is derived 294 by processing of the miR-155HG transcript, our data indicate that this enhancer would be 295 important in controlling miR-155 expression. 296 297 In summary we have identified and characterized new enhancer elements that play a key 298 role in the direct and indirect upregulation of miR-155 expression in EBV infected cells by 299 the EBV transcription factor EBNA2 ( Figure 6 ). Importantly, we show that an EBNA2 and 300 IRF4 responsive enhancer element located 60 kb upstream from the miR-155HG TSS is 301 essential to maintain high level miR-155HG RNA expression. 302 303 DISCUSSION 304
We have characterized an enhancer 60 kb upstream of the miR-155-encoding gene miR-305 155HG that is bound by EBNA2, the key transcriptional regulator encoded by Epstein-Barr 306 virus. We have shown that the presence of this enhancer in the B cell genome is required 307 to maintain high level miR-155HG expression in an EBV-infected B cell line, indicating 308 that enhancer control is critical for miR-155 upregulation by the virus. This enhancer 309 (enhancer 2) was responsive to EBNA2 in reporter assays and EBNA2 activation was 310 dependent on the expression of host cell protein RBPJ. Since EBNA2 cannot bind DNA 311 directly, this is in line with EBNA2 binding via its interaction with RBPJ (36, 37) . MiR-312 155HG enhancer 2 also contains binding sites for a number of other B cell transcription 313 factors (e.g. SPI1 (PU.1), RUNX3, NF-B rel A, BATF and SRF) that likely play a role in 314 regulating its activity in uninfected B cells. It is also possible that some of these 315 transcription factors may help to stabilize EBNA2 or EBNA2-RBPJ binding in the context 316 of B cell chromatin, a scenario that we cannot examine in reporter assays. PU.1 for example 317 has been shown to bind EBNA2 (38). However, in reporter assays loss of RBPJ alone 318 severely diminishes EBNA2 responsiveness indicating that RBPJ is the major mediator of 319 EBNA2 activation of miR-155HG enhancer 2. 320 321 MiR-155HG enhancer 2 is located within a region upstream of miR-155HG that is detected 322
by CHi-C and RNA pol II ChIA-PET to associate with the miR-155HG promoter. 323
Although, another putative enhancer bound by EBNA2 in the GM12878 LCL (enhancer 1) 324 is also present in this region, we found that enhancer 1 was not EBNA2 responsive but did 325 upregulate transcription from the miR-155HG promoter in reporter assays. This indicates 326 that this region possesses EBNA2-independent enhancer function. The detected EBNA2 327 binding at enhancer 1 may therefore be the consequence of looping between enhancer 1 328 and enhancer 2 that would lead to the precipitation of this region of DNA in EBNA2 ChIP 329 experiments. Interestingly, binding at enhancer 1 is not detected by EBNA2 ChIP-seq in a 330 BL cell background (23), so its activity and looping interactions may be cell-type 331 dependent. Two further upstream regions also interact with the miR-155HG promoter by 332
CHi-C and RNA pol II ChIA-PET in LCLs (one intergenic and one proximal to the 333 LINC00158 promoter). This is consistent with the presence of an active enhancer-promoter 334 hub formed between two intergenic enhancer regions (one of which encompasses enhancer 335 2) and the promoter-proximal regions of miR-155HG and LINC00158. In two EBV infected 336 LCL backgrounds (GM12878 and IB4), maximal EBNA2 (and RBPJ) binding at the miR-337 155HG locus is detected in the intergenic interacting region encompassing miR-155HG 338 enhancer 2 (22, 24, 28) . This is despite the classification of the remaining intergenic region 339 and the LINC00158 promoter proximal region as EBV super-enhancers based on their 340 chromatin and TF landscape profiles (28). It is therefore possible that EBNA2 accesses the 341 miR-155HG enhancer hub and upregulates miR-155 expression through its RBPJ-342 dependent association with miR-155HG enhancer 2. Our observations highlight the 343 importance of testing the EBNA2 responsiveness of EBNA2-bound regions rather than 344 relying on binding profiles alone to assign EBNA2 enhancer function. 345
346
The constitutively active EBV membrane protein LMP1 also activates miR-155HG 347 transcription. NF-B and AP-1 sites in the miR-155HG promoter have been shown to be 348 important to maintain miR-155HG promoter activity in LCLs and two NF-B sites and the 349 AP-1 site mediate LMP1 responsiveness in transiently transfected EBV negative cells (18, 350 19) . NF-B RelA also binds to the miR-155HG enhancer 2 region and the putative 351 upstream super-enhancer, so it is also possible that LMP1 activation of the NF-B and AP-352 1 pathways also activates miR-155HG enhancers. Thus promoter (and possibly enhancer) 353 activation by LMP1 and enhancer activation by EBNA2 may all contribute to the high-354 level miR-155 expression observed in EBV-infected cells. 355
356
Our results also revealed that the B cell transcription factor IRF4 can also activate miR-357 155HG transcription via enhancer 2 in addition to its known effects on the miR-155HG 358 promoter. IRF4 activates the miR-155HG promoter via an ISRE. There are no ISREs within 359 miR-155HG enhancer 2, but the 5' sequence of the PU.1 binding site partially matches a 360 reverse ETS-IRF composite element (EICE), so IRF4 could bind in combination with PU.1. 361
In addition to direct control of miR-155 expression through the miR-155HG enhancer, 362 EBNA2 also indirectly influences miR-155 expression through the transcriptional 363 upregulation of IRF4. We demonstrate that again enhancer control by EBNA2 plays an 364 important role in IRF4 activation. In addition to the presence of an EBNA2-bound super-365 enhancer upstream of the neighboring DUSP22 gene (28), we found that EBNA2 can also 366 upregulate IRF4 transcription through an RBPJ dependent enhancer located in an 367 intergenic region 35 kb upstream from IRF4. At IRF4 and DUSP22, EBNA2 therefore 368 likely targets multiple enhancers and super-enhancers. 369 370 MiR-155 is overexpressed in many tumor contexts, including hematological malignancies 371 and is implicated in cancer therapy resistance (11). It therefore represents an important 372 therapeutic target. The first in human phase I trial of a synthetic locked nucleic acid anti-373 miR to miR-155 has been initiated and preliminary results show that the inhibitor is well 374 tolerated in patients with cutaneous T cell lymphoma when injected intratumorally (39). The miR-155HG promoter sequence from -616 to +515 (Human GRCh37/hg19 chr 21 413 26933842-26934972) was synthesized by GeneArt Strings® (Invitrogen) to include XhoI 414 and HindIII restriction enzyme sites and cloned into pGL3 basic (Promega) to generate the 415 pGL3 miR155HG promoter construct. The pGL3miR-155HG enhancer 1 (E1) construct 416 was generated in a similar way by synthesis of the promoter and upstream E1 region (chr21 417 26884583-26885197) as a single DNA fragment that was then cloned into pGL3 basic. To 418 generate the miR-155HG promoter E1 + E2 construct, the promoter and E1 and E2 regions 419 (chr21 26873921-26875152) were synthesized as a single DNA fragment and cloned into 420 pGL3 basic. The pGL3-miR-155HG promoter E2 construct was generated using sequence 421 and ligation independent cloning. The E2 region was amplified by PCR from the miR-422 155HG promoter E1 + E2 construct using primers containing vector and insert sequences 423 (forward 5' 424 TCTTACGCGTGCTAGCCCGGGCTCGAGGAGAGGTTTAAAGCACTCAGACAGC 425 3' and reverse 5' 426 GGGCTTTGAGAACGTTTGTACCTCGAGGATCTAGAACCTCTGGAGTTGGAGA 427 T 3'). The pGL3-miR-155HG promoter vector was digested with XhoI and then T4 DNA 428 polymerase was used to further resect the cut ends to allow the insert to anneal to extended 429 single-stranded regions of the vector. Single-strand DNA gap filling occurred through 430 DNA repair following transformation of the plasmid into E.coli. 431
432
The IRF4 promoter sequence from -739 to +359 (Human GRCh37/hg19 chr6 391024-433 392121) was synthesized by GeneArt (Invitrogen) and the promoter fragment was 434 amplified from the supplied vector (pMK-RQ) using primers to introduce XhoI restriction 435 sites at each end (forward 5' GTCTCGAGATTACAGGCTTGAGCCACA 3', reverse 436 5'GACTCGAGCTGGACTCGGAGCTGAGG 3'). The promoter was then cloned into the 437 Pulser II) using 0.4cm cuvettes and luciferase assays carried out as described previously 452 with some modifications (48). Briefly, DG75 cells were diluted 1:2 into fresh medium 24 453 hours prior to electroporation. For transfection, cells were pelleted and conditioned media 454 reserved for later use. Cells were then resuspended in serum-free media to a density of 455 2x10 7 cells/ml. 500 µl of cell suspension was pre-mixed with DNA and then added to the 456 cuvette and immediately electroporated. Transfected cells were then transferred to 10 ml 457 of pre-warmed conditioned media, and cultured for 48 hours in a humidified incubator at 458 37°C, with 5% CO2. 459
Cells were transfected with 2µg of the pGL3 luciferase reporter plasmids and 0.5µg pRL-460 TK (Promega) as a transfection control where indicated. Transfection reactions also 461 included 10 or 20 µg of the EBNA2 expressing plasmid (pSG5 EBNA2), 5 or 10 µg of 462 IRF4 expressing plasmid (pCMV6XL5-IRF4, Cambridge Biosciences) or empty vector 463 control. One tenth of each transfection was processed for Western blotting to analyse 464 EBNA2, IRF4 and actin protein expression levels. The remaining cells were lysed and 465 firefly and Renilla luciferase activity measured using the dual luciferase assay (Promega) 466 and a Glowmax multi detection system (Promega). For transfections where IRF4 was 467 expressed, firefly luciferase signals were normalized to actin expression. 468 469 CRISPR 470 CRISPR guides were designed using www.benchling.com to excise miR-155HG enhancer 471 2 from the B cell genome in the IB4 LCL by targeting genomic regions located 5' and 3' 472 of the enhancer. Guides were selected that had an on-target and off-target score that was 473 above 60% (26873822 CTATCCTTAACAGAACACCC and 26875376 474 TTTAACTAGAACCTTAGACA) and then ordered as TrueGuide Modified Synthetic 475 sgRNAs from GeneArt (Invitrogen). IB4 cells were diluted 1:2 into fresh medium 24 hours 476 prior to transfection. 1x10 6 cells were then washed in PBS, pelleted and resuspended in 25 477 µl of resuspension Buffer R (Invitrogen). The guide RNA and Cas9 mix was prepared by 478 adding 7.5 pmol of GeneArt TrueCut Cas9 Protein V2 (Invitrogen) and 7.5 pmol of 479 sgRNAs to 5 μl of resuspension Buffer R and incubating at room temperature for 10 480 minutes. 5 μl of cell suspension (2 x10 5 cells) was then mixed with 7ul of the Cas9/sgRNA 481 complex. 10ul of the cell Cas9/sgRNA mix was then electroporated using the Neon 482 transfection system (Invitrogen) at 1700V for 20 ms with 1 pulse. Transfections were 483 carried out in duplicate and electroporated cells were immediately transferred to two 484 separate wells of a 24 well plate containing 0.5 ml of pre-warmed growth media. Cells 485 were kept in a humidified incubator at 37°C, with 5% CO2 for 72 hours. Cells were then 486 sequentially diluted over a period of 2 weeks and subject to limited dilution in 96 well 487
plates to obtain single cell clones. Cell line clones were screened by PCR for genomic 488 deletion using the PHIRE Tissue Direct PCR Master Mix kit (Thermo Scientific). The 489 forward primer (5' AAATTCCGTGGCTAGCTCCA 3') hybridized to a region 5' of 490 enhancer 2 and two different reverse primers targeted either a region within enhancer 2 491 (reverse primer 1, 5' AATGGGATGGCTGTCTGAGT 3') or a region 3' to enhancer 2 492 (reverse primer 2, 5' CTGCTAAGGGAATGTTGAACAAA 3'). Deletions were 493 confirmed by DNA sequencing of the PCR product generated using the forward PCR 494 primer. 495
496
SDS-PAGE and Western Blotting 497
SDS-PAGE and Western blotting was carried out as described previously (48, 49) using 498 the anti-EBNA2 monoclonal antibody PE2 (gift from Prof M. Rowe) anti-actin 1/5000 (A-499 2066, Sigma) and IRF4 1/2000 (sc6059, Santa Cruz). Western blot visualization and signal 500 quantification was carried out using a Li-COR Imager. 501 502
ChIP-QPCR 503
ChIP-QPCR for RBPJ was carried out as described previously (24). MiR-155HG locus 504 primers were located in the miR-155HG promoter (forward 5' 505 AGCTGTAGGTTCCAAGAACAGG 3' and reverse 5' 506 GACTCATAACCGACCAGGCG 3', miR-155HG enhancer 1 (forward 5' 507 ACCTGTTGACTTGCCTAGAGAC 3' and reverse 5' TTCTGGTCTGTCTTCGCCAT 508 3'), a 'trough' region between miR-155HG enhancer 1 and enhancer 2 (forward 5' 509 TATTCAGCTATTCCAGGAGGCAG 510 3' and reverse 5' GTGACATTATCTGCACAGCGAG 3'), and miR-155HG enhancer 2 511 (forward 5' CCTAGTCTCTCTTCTCCATGAGC 3' and reverse 5' 512 AGTTGATTCCTGTGGACCATGA 3'). IRF4 locus primers were located in the IRF4 513 promoter (forward 5' TCCGTTACACGCTCTGCAA 3' and reverse 5' 514 CCTCAGGAGGCCAGTCAATC 3'), a 'trough' region between the IRF4 promoter and 515 enhancer 1 (forward 5' TGTGACAAGTGACGGTATGCT 3' and reverse 5' 516 TTGTAACAGCGCCTAATGTTGG 3'), IRF4 enhancer 1 (forward 5' 517 TTACCACCTGGGTACCTGTCT 3' and reverse 5' ACAGTAGCATGCAGCACTCTC 518 3') and IRF4 enhancer 2 (forward 5' AGTGAGACGTGTGTCAGAGG 3' and reverse 5' 519 AAGCAGGCACTGTGATTCCA 3'). 520
521
RT-QPCR 522
Total RNA was extracted using TriReagent (Sigma) and RNA samples then purified using 523 the RNeasy kit (Qiagen). RNA concentrations were determined using a Nanodrop 2000 524 (Thermo Scientific) and 1 μg was used to prepare cDNA using the ImProm II reverse 525 transcription kit with random primers (Promega). Quantitative PCR was performed in 526 duplicate using the standard curve absolute quantification method on an Applied 527 Biosystems 7500 real-time PCR machine as described previously (23) Capture Hi-C 535 Previously described capture Hi-C data from GM12878 and CD34+ cells were examined 536 for interactions that were captured using baits comprising a 13,140 bp HindIII fragment 537 encompassing the mIR-155HG promoter (GRCh38/hg19 chr21:26926437-26939577) and 538 a 2,478 bp HindIII fragment that encompasses the miR-155 genomic sequence in exon 3 539 (GRCh38/hg19 chr21:26945874-26948352). were transfected with 2 µg of pGL3 firefly luciferase reporter constructs containing the 768 miR-155HG promoter either alone or in the presence of enhancer E1, E2 or both E1 and 769 E2. Assays were carried out in the absence or presence of 5 or 10 µg of the IRF4-expressing 770 plasmid pCMV6XL5-IRF4. Western blot analysis of IRF4 and actin expression is shown 771 below the bar chart. Firefly luciferase signals were normalized to actin western blot signals 772 and fold activation relative to the signal for each construct in the absence of EBNA2 is 773 shown. Results show the mean of three independent experiments plus or minus standard 774 deviation. 775 were transfected with 2 µg of pGL3 firefly luciferase reporter constructs containing the 780 IRF4 promoter either alone or in the presence of enhancer E1 or both E1 and E2. Assays 781 were carried out in the absence or presence of 10 or 20 µg of the EBNA2-expressing 782 plasmid pSG5-EBNA2 and 0.5 µg of Renilla luciferase control plasmid (pRL-TK). Firefly 783 luciferase signals were normalized to Renilla luciferase signals and expressed relative to 784 the signal obtained for the IRF4 promoter in the absence of EBNA2. EBNA2 activation of 785 an EBV C promoter reporter construct was used as a positive control. Results show the 786 mean of three independent experiments plus or minus standard deviation. Fold activation 787 by EBNA2 relative to the signal obtained for each construct in the absence of EBNA2 is 788 shown above each bar. Western blot analysis of EBNA2 is shown below each bar chart, 789 with actin providing a loading control. (C) ChIP-QPCR analysis of RBPJ binding at the 790 IRF4 locus in GM12878 cells. Precipitated DNA was analysed using primer sets located at 791 the promoter, E1, E2 and in a trough between the promoter and E1 (T). EBNA2 binding at 792 the transcription start site of PPIA and at the previously characterised CTBP2 binding site 793 were used as negative and positive binding controls, respectively. Mean percentage input 794 signals, after subtraction of no antibody controls, are shown plus or minus standard 795 deviation for three independent ChIP experiments. (D) Luciferase reporter assays carried 796 out using the IRF4 promoter, IRF4 E1 and E2 construct and the RBPJdependent C 
